skvi-logo-360w-65t

INVISICARE-IMAGE

Skinvisible Pharmaceuticals, Inc.
(OTCBB: SKVI)

Dear Members,

When I say we have known the people from Skinvisible for four years, that is really like almost five years. In June it will be five years when we first started our coverage of Skinvisible. We have covered them several times over these years. The Company has moved forward on a regular basis and now has some great opportunities coming its way.

First – it is a company selling products. This is not a pure research play. There are revenues and there are products at market. There have been for years.

Over the years I have visited with the Company and have had the chance to see how they conduct some of their research first hand.  There is nothing like visiting a company to get to know the character of the company. There are a lot of great people at Skinvisible, and the research they are doing every day will benefit all of us over time.

I am going to give you a quick overview of the Company, and then explain where I see value here.  Let’s start with that overview.

This “Overview” was taken from their site.  It is the best explanation of what they do – in general:

Skinvisible, Inc., through its wholly owned subsidiary, Skinvisible Pharmaceuticals, Inc., is an R&D pharmaceutical company that develops enhanced, patent protected dermatology and healthcare products including products to treat acne, skin cancers, eczema, fungal infections, inflammation, warts and dermatitis along with sunscreens, anti-aging products, alcohol-free hand sanitizing lotions, pre-surgical preparations, and various other medical treatments using its patented technology Invisicare®. Skinvisible’s primary objective is to license these prescription and over-the-counter products into the $65 billion global dermatology market and other medical markets. Potential licensees include international and multi-national pharmaceutical, cosmetic, skincare and consumer goods companies seeking new products, product enhancements or life cycle management for their existing products.

The Technology: Invisicare® is a patented technology that enhances how drugs are delivered on, in or through the skin. It can control the release of active ingredients, providing a greater and longer release, while at the same time reducing irritation to the skin. It also binds products to the skin for 4 hours and more, resisting wash-off and rub-off. Skinvisible has developed a portfolio of 40+ topical products using Invisicare (prescription, over-the-counter and cosmeceutical) and also works directly with companies to enhance their products, especially ones coming off patent. Invisicare can be tailored to almost any type of molecule and the needs our customers.

 

invisicare-265-110

Let’s look at Invisicare:

This “polymer delivery system” is really a method of delivering an active ingredient for topical application on the skin.  Their formula is patented and protected to such an extent it really cannot be duplicated by other pharmaceuticals.

Here is a more thorough explanation from the Invisicare website:

Invisicare is specifically formulated to carry water insoluble active and certain cationic active ingredients in water-based products without the use of alcohol, silicones, waxes, or other organic solvents. Products utilizing Invisicare have the proven ability to bond active ingredients to the skin for up to four hours and longer. They are non-occlusive and allow normal skin respiration and perspiration while moisturizing and protecting against exposure from a wide variety of environmental irritants.

When topically applied, these formulated products adhere to the skin’s outer layers, forming a protective bond, resisting wash-off, and delivering targeted levels of therapeutic or cosmetic skincare agents to the skin. They allow enhanced delivery performance for a variety of skincare agents resulting in improved efficacy, longer duration of action, reduced irritation and lower dosage of active agent required. The “invisible” polymer compositions wear off as part of the natural exfoliation process of the skin’s outer layer cells. 

LATER TODAY:

  • We are going to look at Skinvisible’s potential for an orphan drug that potentially brings relief to sufferers of a little known condition, Netherton Syndrome.
  • Many Skinvisible Products are already on the market. We will take a look at these.
  • Valuation: How do we value shares of Skinvisible?

 

MORE INFORMATION ON SKINVISIBLE:

skvi-logo-360w-65t

Skinvisible Pharmaceuticals, Inc. (OTCBB: SKVI)

 

CORPORATE CONTACT:

Doreen McMorran
Skinvisible Pharmaceuticals, Inc.
Phone: 702-433-7154
Email: [email protected]

ON THE WEB:

Skinvisible.com

Invisicare.com

 

 

Disclosures: We hold no shares of Skinvisible stock, and are not contracted to receive shares during the present period of coverage. We do not anticipate receiving shares either from the company or any third party.  Had we had shares, we avoid all potential conflicts of interest, as we never sell shares into the open market during an active market awareness or investor relations program. This means that as we release new information about a particular client company either on our site or otherwise authored by us, you can be confident we are not selling shares at the same time. StockGuru is not a registered investment adviser or a broker/dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.  StockGuru is retained by Skinvisible for consulting purposes and investor awareness. We have received a total of six thousand two hundred dollars in payments. Previously for coverage in 2009, we were compensated and once held five hundred thousand shares of 144 restricted stock. We anticipate receiving up to six thousand dollars potentially over the next 180 days. We do not anticipate receiving shares of any kind, restricted or otherwise. StockGuru is STOCKGURU.COM. 1601 Berwick Drive, McKinney, Texas 75070 – (469) 252-3030.